MicroRNA 3929 (MIR3929)

MicroRNA 3929 is a human microRNA (hsa-mir-3929) belonging to the microRNA family of small non-coding RNAs approximately 21–23 nucleotides in length. Like other miRNAs, MIR3929 is processed from a precursor transcript through the canonical DROSHA/DICER pathway, resulting in a mature molecule that regulates gene expression at the post-transcriptional level—primarily by binding to complementary sites in the 3' untranslated region of target messenger RNAs, leading to their degradation or translational repression. While the specific biological targets and disease associations of MIR3929 are not extensively mapped, its molecular class and regulatory functions suggest possible roles in cancer and other complex cellular processes, like cell differentiation, proliferation, apoptosis, and immune responses. Therapeutic approaches for microRNAs typically involve nucleic acid-based drugs intended to modulate abnormal miRNA activity in disease. Overexpression or suppression of miRNAs, including those like MIR3929, can potentially affect multiple pathways, and their detection in body fluids also makes them valuable as disease biomarkers, especially in oncology.

Other names

hsa-mir-3929MIR3929miR-3929

Antisense inhibition (via oligonucleotide binding); Replacement therapy by mimics; Modulation by small molecules targeting the microRNA biogenesis pathway. These mechanisms are typical for miRNA therapeutic strategies.